Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 6:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 14,654 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Once daily Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Administration of Itraconazole on the Pharmacokinetics of S-309309 in Healthy Participants

NCT06106334
View directory record Official record
Conditions
Obesity, Healthy Volunteers
Interventions
S309309, Itraconazole
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Sep 28, 2026, 6:17 AM EDT
Completed Phase 3 Interventional Results available

Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events

NCT01730534
View directory record Official record
Conditions
Diabetes Mellitus, Non-Insulin-Dependent, High Risk for Cardiovascular Event
Interventions
Dapagliflozin 10 mg, Placebo tablet
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 130 Years
Enrollment
17,190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
234
States / cities
Alexander City, Alabama • Athens, Alabama • Birmingham, Alabama + 202 more
Source: ClinicalTrials.gov public record
Updated Dec 25, 2019 · Synced Sep 28, 2026, 6:17 AM EDT
Completed Phase 2 Interventional Results available

A Two-dose Level Clinical Trial of Itraconazole in Patients With Metastatic Prostate Cancer Who Have Had Disease Progression While on Hormonal Therapy

NCT00887458
View directory record Official record
Conditions
Prostate Cancer
Interventions
Itraconazole 200 mg, Itraconazole 300mg
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older · Male only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
4
States / cities
Baltimore, Maryland • Ann Arbor, Michigan • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2017 · Synced Sep 28, 2026, 6:17 AM EDT
Not yet recruiting Phase 2 Interventional Accepts healthy volunteers

Use of Bile Acid Binding Resins to Decrease PFAS Levels Via Colesevalem in Veterans Study

NCT07592858
View directory record Official record
Conditions
PFAS, Environmental Exposures, Occupational Exposure to Chemicals, Military Exposure, Burn Pit Exposure, Forever Chemicals, Hyperlipidemias, Hypercholesterolemia, Mixed Dyslipidemia, Hyperlipidemia (E.G., Hypercholesterolemia)
Interventions
Colesevelam, Placebo
Drug
Lead sponsor
University of Rhode Island
Other
Eligibility
25 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
2
States / cities
Louisville, Kentucky • Augusta, Maine
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Sep 28, 2026, 6:17 AM EDT
Enrolling by invitation Phase 3 Interventional

Reduce Opiate Exposure With ACL Surgery

NCT06561035
View directory record Official record
Conditions
Anterior Cruciate Ligament Injuries
Interventions
Opiate Sparing, Opiate Based
Drug
Lead sponsor
Campbell Clinic
Other
Eligibility
14 Years to 85 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
3
States / cities
Skokie, Illinois • Cincinnati, Ohio • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 28, 2026, 6:17 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Quercetin's Effect on Bone Health and Inflammatory Markers

NCT05371340
View directory record Official record
Conditions
Osteoporosis, Postmenopausal
Interventions
Quercetin (500 mg), Placebo (500 mg)
Dietary Supplement · Other
Lead sponsor
Kennesaw State University
Other
Eligibility
45 Years to 75 Years · Female only
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Kennesaw, Georgia
Source: ClinicalTrials.gov public record
Updated May 11, 2022 · Synced Sep 28, 2026, 6:17 AM EDT
Completed Phase 2 Interventional Results available

Dose Response Study of GSK2330672 for the Treatment of Pruritus in Participants With Primary Biliary Cholangitis

NCT02966834
View directory record Official record
Conditions
Cholestasis
Interventions
Placebo, GSK2330672
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
9
States / cities
Phoenix, Arizona • Sacramento, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated May 3, 2021 · Synced Sep 28, 2026, 6:17 AM EDT
Completed Phase 3 Interventional

A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)

NCT04777409
View directory record Official record
Conditions
Early Alzheimer´s Disease
Interventions
Semaglutide, Placebo (semaglutide)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
55 Years to 85 Years
Enrollment
1,840 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
107
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 85 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Sep 28, 2026, 6:17 AM EDT
Completed Phase 4 Interventional Results available

Effects of a Orally Inhaled Fluticasone Furoate on Growth Velocity in Prepubertal, Paediatric Subjects With Asthma Over a Year

NCT02889809
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone furoate, Placebo, Montelukast, Short Acting Beta 2 Agonist
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
5 Years to 9 Years
Enrollment
477 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
18
States / cities
Little Rock, Arkansas • Huntington Beach, California • Homestead, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2024 · Synced Sep 28, 2026, 6:17 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Alendronate to Prevent Loss of Bronchoprotection in Asthma

NCT02230332
View directory record Official record
Conditions
Asthma
Interventions
Alendronate, Placebo
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
10
States / cities
Tucson, Arizona • San Francisco, California • Denver, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2018 · Synced Sep 28, 2026, 6:17 AM EDT
Completed Phase 4 Interventional Results available

Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia

NCT05859698
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder, Tardive Dyskinesia
Interventions
Valbenazine
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
18
States / cities
Bryant, Arkansas • Anaheim, California • Orange, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Sep 28, 2026, 6:17 AM EDT
Completed Phase 3 Interventional

A Multi-center Study to Evaluate the Safety and Efficacy of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on Non-head Locations (Trunk and Extremities)

NCT00917306
View directory record Official record
Conditions
Actinic Keratosis
Interventions
PEP005 Gel
Drug
Lead sponsor
Peplin
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
8
States / cities
Orange Park, Florida • Newnan, Georgia • Snellville, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2015 · Synced Sep 28, 2026, 6:17 AM EDT
Terminated Phase 1 Interventional

Study of Grifola Frondosa (Maitake), Azacitidine, and Lenalidomide

NCT01200004
View directory record Official record
Conditions
Advanced Cancers
Interventions
Azacitidine, Lenalidomide, Grifola Frondosa
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
13 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 1, 2013 · Synced Sep 28, 2026, 6:17 AM EDT
Terminated Phase 3 Interventional Results available

Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery

NCT01011478
View directory record Official record
Conditions
Colorectal Cancer, Precancerous Condition
Interventions
rosuvastatin, placebo
Drug · Other
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older
Enrollment
406 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
584
States / cities
Anniston, Alabama • Mobile, Alabama • Fort Smith, Arkansas + 423 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2023 · Synced Sep 28, 2026, 6:17 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Complementary and Alternative Medicine for Urological Symptoms(CAMUS)

NCT00603304
View directory record Official record
Conditions
Urological
Interventions
Saw Palmetto - first 24 weeks, Placebo - first 24 weeks, Saw Palmetto - weeks 24 - 48, Placebo - weeks 24 - 48, Saw Palmetto - weeks 48 - 72, Placebo - weeks 48 - 72
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
45 Years and older · Male only
Enrollment
369 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
10
States / cities
Oakland, California • Aurora, Colorado • New Haven, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2012 · Synced Sep 28, 2026, 6:17 AM EDT
Completed Phase 1 Interventional

A Study to Investigate the Safety, Tolerability, Pharmacokinetic, and Efficacy of ABY-035/AFO2

NCT03580278
View directory record Official record
Conditions
Psoriasis
Interventions
ABY-035/AFO2
Biological
Lead sponsor
Affibody
Industry
Eligibility
18 Years to 70 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Encino, California
Source: ClinicalTrials.gov public record
Updated Jan 24, 2022 · Synced Sep 28, 2026, 6:17 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Naltrexone and Hypoglycemia in Type 1 Diabetes

NCT01053078
View directory record Official record
Conditions
Type 1 Diabetes, Hypoglycemia Unawareness
Interventions
Naltrexone, Placebo
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 4, 2020 · Synced Sep 28, 2026, 6:17 AM EDT
Completed Phase 3 Interventional Results available

Pilot Trial of Deferasirox in the Treatment of Porphyria Cutanea Tarda

NCT00599326
View directory record Official record
Conditions
Porphyria Cutanea Tarda
Interventions
Deferasirox
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 9, 2014 · Synced Sep 28, 2026, 6:17 AM EDT
Completed Phase 2 Interventional Results available

Vorinostat and Rituximab in Treating Patients With Indolent Non-Hodgkin Lymphoma

NCT00720876
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab, vorinostat
Biological · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
3
States / cities
Beverly Hills, California • Duarte, California • Pasadena, California
Source: ClinicalTrials.gov public record
Updated Aug 6, 2018 · Synced Sep 28, 2026, 6:17 AM EDT
Completed Phase 4 Interventional Results available

PORtopulmonary Hypertension Treatment wIth maCitentan - a randOmized Clinical Trial

NCT02382016
View directory record Official record
Conditions
Portopulmonary Hypertension
Interventions
Macitentan, Placebo
Drug · Other
Lead sponsor
Actelion
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
29
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2025 · Synced Sep 28, 2026, 6:17 AM EDT
Completed Phase 1 Interventional

Phase I Study of Induction Therapy With VELCADE and Vorinostat in Patients With Surgically Resectable Non-Small Cell Lung Cancer

NCT00731952
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Velcade and Vorinostat
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 3, 2017 · Synced Sep 28, 2026, 6:17 AM EDT
Completed Phase 3 Interventional Results available

Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®

NCT01696058
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Tiotropium, Placebo matching Olodaterol, Olodaterol
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
1,137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
94
States / cities
Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 82 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2014 · Synced Sep 28, 2026, 6:17 AM EDT
Recruiting Early Phase 1 Interventional

Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic Leukemia

NCT07071155
View directory record Official record
Conditions
Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Myeloproliferative Overlap Neoplasms, Chronic Neutrophilic Leukemia
Interventions
Momelotinib, Azacitidine
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 28, 2026, 6:17 AM EDT
Terminated Phase 3 Interventional Results available

Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 3)

NCT03400943
View directory record Official record
Conditions
Uterine Fibroids
Interventions
Vilaprisan (BAY1002670), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Female only
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
52
States / cities
Birmingham, Alabama • Arcadia, California • Cerritos, California + 43 more
Source: ClinicalTrials.gov public record
Updated May 2, 2023 · Synced Sep 28, 2026, 6:17 AM EDT